175 related articles for article (PubMed ID: 9390198)
1. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2.
Kruse CA; Cepeda L; Owens B; Johnson SD; Stears J; Lillehei KO
Cancer Immunol Immunother; 1997 Oct; 45(2):77-87. PubMed ID: 9390198
[TBL] [Abstract][Full Text] [Related]
2. Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours.
Kruse CA; Beck LT
Biotechnol Appl Biochem; 1997 Jun; 25(3):197-205. PubMed ID: 9198273
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.
Quattrocchi KB; Miller CH; Cush S; Bernard SA; Dull ST; Smith M; Gudeman S; Varia MA
J Neurooncol; 1999; 45(2):141-57. PubMed ID: 10778730
[TBL] [Abstract][Full Text] [Related]
4. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics.
Kronik N; Kogan Y; Vainstein V; Agur Z
Cancer Immunol Immunother; 2008 Mar; 57(3):425-39. PubMed ID: 17823798
[TBL] [Abstract][Full Text] [Related]
5. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes.
Merchant RE; Baldwin NG; Rice CD; Bear HD
Neurol Res; 1997 Apr; 19(2):145-52. PubMed ID: 9175143
[TBL] [Abstract][Full Text] [Related]
7. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.
Hayes RL; Koslow M; Hiesiger EM; Hymes KB; Hochster HS; Moore EJ; Pierz DM; Chen DK; Budzilovich GN; Ransohoff J
Cancer; 1995 Sep; 76(5):840-52. PubMed ID: 8625188
[TBL] [Abstract][Full Text] [Related]
8. Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes.
Tsurushima H; Liu SQ; Tuboi K; Matsumura A; Yoshii Y; Nose T; Saijo K; Ohno T
Jpn J Cancer Res; 1999 May; 90(5):536-45. PubMed ID: 10391094
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.
Sloan AE; Dansey R; Zamorano L; Barger G; Hamm C; Diaz F; Baynes R; Wood G
Neurosurg Focus; 2000 Dec; 9(6):e9. PubMed ID: 16817692
[TBL] [Abstract][Full Text] [Related]
10. Systemic T cell adoptive immunotherapy of malignant gliomas.
Plautz GE; Barnett GH; Miller DW; Cohen BH; Prayson RA; Krauss JC; Luciano M; Kangisser DB; Shu S
J Neurosurg; 1998 Jul; 89(1):42-51. PubMed ID: 9647171
[TBL] [Abstract][Full Text] [Related]
11. Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma.
Yamanaka R; Honma J; Tsuchiya N; Yajima N; Kobayashi T; Tanaka R
J Neurooncol; 2005 Apr; 72(2):107-13. PubMed ID: 15925989
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy.
Lillehei KO; Mitchell DH; Johnson SD; McCleary EL; Kruse CA
Neurosurgery; 1991 Jan; 28(1):16-23. PubMed ID: 1994273
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
14. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.
Kruse CA; Lillehei KO; Mitchell DH; Kleinschmidt-DeMasters B; Bellgrau D
Proc Natl Acad Sci U S A; 1990 Dec; 87(24):9577-81. PubMed ID: 2263613
[TBL] [Abstract][Full Text] [Related]
15. Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor.
Kitahara T; Watanabe O; Yamaura A; Makino H; Watanabe T; Suzuki G; Okumura K
J Neurooncol; 1987; 4(4):329-36. PubMed ID: 3494820
[TBL] [Abstract][Full Text] [Related]
16. [Cellular immunotherapy for malignant glioma].
Okamoto Y; Yamashita J
Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
[No Abstract] [Full Text] [Related]
17. Salvage immunotherapy of malignant glioma.
Ingram M; Jacques S; Freshwater DB; Techy GB; Shelden CH; Helsper JT
Arch Surg; 1987 Dec; 122(12):1483-6. PubMed ID: 3500693
[TBL] [Abstract][Full Text] [Related]
18. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
[TBL] [Abstract][Full Text] [Related]
19. Autologous natural killer cell therapy for human recurrent malignant glioma.
Ishikawa E; Tsuboi K; Saijo K; Harada H; Takano S; Nose T; Ohno T
Anticancer Res; 2004; 24(3b):1861-71. PubMed ID: 15274367
[TBL] [Abstract][Full Text] [Related]
20. Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells.
Holladay FP; Lopez G; De M; Morantz RA; Wood GW
Neurosurgery; 1992 Apr; 30(4):499-504; discussion 504-5. PubMed ID: 1584347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
